UK markets close in 2 hours 35 minutes

Black Diamond Therapeutics, Inc. (BDTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.07+0.17 (+3.47%)
As of 09:54AM EDT. Market open.

Black Diamond Therapeutics, Inc.

One Main Street
14th Floor
Cambridge, MA 02142
United States
617 252 0848
https://www.blackdiamondtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees54

Key executives

NameTitlePayExercisedYear born
Dr. Mark A. Velleca M.D., Ph.D.CEO, President & Chairman43.89kN/A1964
Dr. David M. Epstein Ph.D.Co-Founder & Director885.08kN/A1959
Dr. Fang Ni Pharm.D.CFO, Principal Financial Officer and Chief Business Officer656.33kN/A1987
Mr. Brent Hatzis-Schoch Esq., J.D.COO & General Counsel683.29kN/A1965
Dr. Elizabeth Buck Ph.D.Co-Founder & Chief Scientific Officer340.47kN/A1975
Ms. Erika JonesVP of Finance, Corporate Controller & Principal Accounting OfficerN/AN/A1985
Ms. Elizabeth L. MontgomeryChief People OfficerN/AN/A1972
Dr. Sergey Yurasov M.D., Ph.D.Chief Medical OfficerN/AN/A1969
Ms. Melanie MorrisonChief Development OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Black Diamond Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.